Colin Young

Dr. Colin Young

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Genes
Verified
Journal Article
Open access
PDF file
HZHeather Zimmermann
Heather Zimmermann
TBTerra Brannan
Terra Brannan
CYColin Young
Colin Young
JCJesus Ramirez Castano
Jesus Ramirez Castano
CHCarolyn Horton
Carolyn Horton
MRMarcy E Richardson
Marcy E Richardson
Background: Germline genetic variants impacting splicing are a frequent cause of disease. The clinical interpretation of such variants is challenging for many reasons including the immense complexity of splicing mechanisms. While recent advances in splicing algorithms have improved the accuracy of splice prediction, predicting the nature and abundance of aberrant splicing remains challenging. As RNA testing becomes more mainstream in the clinical diagnostic setting, the complexities of interpretation are coming to light. Methods: Data from patients undergoing concurrent DNA and RNA testing were retrospectively reviewed for unusual splicing impacts to underscore some of these complexities and serve as exemplars in how to avoid pitfalls in the interpretation of sequence variants. Results: Seven rare variants with unusual splicing impacts are presented: a variant at a consensus donor nucleotide position lacking a splice impact (NF1 c.888+2T>C); a mid-exonic missense variant creating a novel donor site and a cryptic acceptor site resulting in pseudo-intronization (BRIP1 c.727AA p.Ala744Ala); two variants that would be expected to result in nonsense-mediated-mRNA-decay triggering splicing impacts that obviated nonsense-mediated-decay (APC c.1042C>T p.Arg348Ter and BRCA2 c.6762del; c.6816_6841+1534del); and two variants causing splicing impacts through pyrimidine tract optimization (NF1 c.5750-184_5750-178dup and ATM c.3480G>T p.Val1160Val). Conclusions: Paired DNA and RNA testing revealed unexpected splice events altering variant interpretation, expanding our knowledge of clinically important splicing mechanisms and highlighting the benefit of RNA testing.

30 May 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CYColin Young
Colin Young
ALAshley Lahr
Ashley Lahr
CNCaroline Nestor
Caroline Nestor
AKAshley Kaminski
Ashley Kaminski
MRMarcy E Richardson
Marcy E Richardson
GAGeorgianne L. Arnold
Georgianne L. Arnold
Pathogenic alterations in BRCA1 are associated with autosomal dominant breast and ovarian cancer and autosomal recessive Fanconi Anemia Subtype S (FA-S). FA-S accounts for A, p.C64Y and c.3991C>T, p.Q1331*) were identified in trans. At four years old, this patient has not been diagnosed with cancer or bone marrow failure, which are hallmark features in other subtypes of FA. Like a majority of the literature-reported FA-S patients, this patient harbors a truncating variant in BRCA1 exon 11. This exon undergoes alternative splicing resulting in a protein with partial BRCA1 activity. The retained activity may be enough to rescue an otherwise lethal phenotype explaining the viability of FA-S patients. This retained functional activity may also modify clinical cancer risks and treatment implications for heterozygous carriers of exon 11 truncating variants. This work further characterizes the features of FA-S patients and discusses a molecular hypothesis for the rarity and viability of individuals with this condition.